ASP Isotopes Inc. has announced a significant supply agreement with Isotopia Molecular Imaging Ltd. for enriched gadolinium-160 (Gd-160), a crucial precursor isotope for producing terbium-161 (Tb-161), an emerging medical isotope with substantial potential in targeted radiotherapeutics.
The four-year supply agreement, commencing in 2026, is expected to have a minimum contract value of $1 million per annum. This collaboration addresses longstanding supply challenges for Gd-160, enabling Isotopia to advance Tb-161-based therapies for prostate cancer, neuroendocrine tumors, and other malignancies.
ASP Isotopes will leverage its proprietary quantum enrichment technology to provide Isotopia with enriched Gd-160, essential for manufacturing Tb-161. This partnership accelerates the path to clinical adoption of Tb-161, which could redefine cancer treatment paradigms.
Isotopia has consistently manufactured lutetium-177 (Lu-177) and maintained weekly Tb-161 production for its clinical trials over the past two years. This collaboration combines ASP Isotopes' expertise in large-scale isotope enrichment with Isotopia's proven capabilities in commercial-scale medical isotope production.
Dr. Eli Shalom, CEO of Isotopia, highlighted Tb-161's therapeutic advantages, emphasizing its dual mechanism of action, including auger electron emissions that enable precise targeting of micro-metastases while minimizing damage to healthy tissues.
ASP Isotopes' CEO, Paul Mann, emphasized the agreement's significance, stating that by supplying Gd-160, they are eliminating a major bottleneck in the development of Tb-161 therapies. This partnership ensures a reliable Gd-160 supply chain, allowing Isotopia to scale production and advance Tb-161-labeled drug candidates toward commercialization.
The partnership positions both companies at the forefront of the radiopharmaceutical revolution, with the potential to expand treatment options for cancer patients worldwide.
ASP Isotopes is also in discussions with other customers who require Gd-160 and expects to sign additional orders during 2025.
The company's quantum enrichment process, a novel laser-based approach to enriching isotopes, is expected to be utilized for enriching Gd-160. This process will be part of a large quantum plant that the company is in the process of designing and constructing.
ASP Isotopes is a development stage advanced materials company dedicated to the development of technology and processes to produce isotopes for use in multiple industries. The company's initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries.
This partnership signifies a significant step forward in the production and supply of critical isotopes for advanced cancer therapies and highlights the companies' commitment to addressing the challenges in the medical isotope supply chain. Following these announcements, the company's shares moved 9.08%, and are now trading at a price of $8.65. For the full picture, make sure to review ASP Isotopes's 8-K report.
